**About the Editor**

## **Stephane Dedieu**

Professor Stephane Dedieu holds a Ph.D. from the University of Bordeaux (France) where he ´ was trained in biochemistry and molecular biology during the early 2000s. He currently co-leads a 40 people research team within a multidisciplinary CNRS labelled unit (UMR CNRS 7369 MEDyC) affiliated to the University of Reims. He has expertise in cancer biology and therapeutic targeting of the extracellular matrix and cellular receptors.

He co-founded Apmonia Therapeutics, a biotechnology company dedicated to the development of anti-cancer strategies and is chair of the scientific and clinical advisory board of the company.
